n-methyl-3,4-methylenedioxyamphetamine has been researched along with psilocybin in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (13.73) | 29.6817 |
| 2010's | 7 (13.73) | 24.3611 |
| 2020's | 37 (72.55) | 2.80 |
| Authors | Studies |
|---|---|
| Ghuran, A; Nolan, J | 1 |
| Check, E | 1 |
| Cuddy, ML | 1 |
| Biello, D | 1 |
| Hunt, N; McCambridge, J; Mitcheson, L; Winstock, A | 1 |
| Amorosi, DJ; Rabin, RA; Rice, KC; Winter, JC | 1 |
| Fantegrossi, WE; Katz, EB; Reissig, CJ; Rice, KC; Winter, JC; Yarosh, HL | 1 |
| Gamma, A; Studerus, E; Vollenweider, FX | 1 |
| Brewerton, TD; Grob, CS; Mithoefer, MC | 1 |
| Gallinat, J; Hermle, L; Jungaberle, H; Majić, T; Schmidt, TT; Zeuch, A | 1 |
| Sessa, B | 1 |
| Carhart-Harris, RL; Gabay, AS; Kempton, MJ; Mazibuko, N; Mehta, MA; Morrison, PD; Nutt, DJ | 1 |
| Heifets, BD; Malenka, RC | 1 |
| Nutt, D | 1 |
| Carpenter, LL; Kalin, NH; McDonald, WM; Nemeroff, CB; Reiff, CM; Richman, EE; Rodriguez, CI; Widge, AS | 1 |
| Abbott, KL; Boothe, DM; Dhanasekaran, M; Flannery, PC; Gill, KS; Pondugula, SR | 1 |
| Greif, A; Šurkala, M | 1 |
| Cha, DS; Chen-Li, D; El-Halabi, S; Gill, B; Gill, H; Ho, R; Lee, Y; Lipsitz, O; Majeed, A; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD | 1 |
| Aguilar-Valles, A; De Gregorio, D; Gobbi, G; Heifets, BD; Hibicke, M; Mitchell, J; Preller, KH | 1 |
| Tullis, P | 1 |
| Bates, MLS; Trujillo, KA | 1 |
| Cusimano, J; Hosanagar, A; Radhakrishnan, R | 2 |
| de la Salle, S; Fogg, C; Jahn, ZW; Michaels, TI; Williams, MT | 1 |
| Bird, CIV; Modlin, NL; Rucker, JJH | 1 |
| Barnett, BS; Parker, SE; Weleff, J | 1 |
| Holze, F; Liechti, ME | 1 |
| Jones, GM; Nock, MK | 3 |
| Erdmann, M; Hase, A; Hasler, G; Limbach, V | 1 |
| Malcolm, B; Sarparast, A; Stauffer, CS; Thomas, K | 1 |
| Connor, M; Kisely, S; Siskind, D; Somogyi, AA | 1 |
| Benedek, DM; Canales, JJ; Eri, R; Johnson, LR; Marathe, PA; Raut, SB; Ravindran, M; Ursano, RJ; van Eijk, L | 1 |
| Anderson, BT; Averill, LA; Belouin, SJ; Berger, A; Danforth, AL; Donato, I; Grob, CS; Henningfield, JE; Magar, V; Xenakis, SN | 1 |
| Breeksema, JJ; Kamphuis, J; Kuin, BW; Schoevers, RA; van den Brink, W; Vermetten, E | 1 |
| Aaronson, ST; Barber, GS | 1 |
| Anderson, B; Grob, C; Johnston, CB; Mangini, M | 1 |
| Jones, GM | 1 |
| Daily, JE; Nicol, GE; Perry, DA; Siegel, JS | 1 |
| Arias, D; Jones, G; Nock, M | 1 |
| Dalo, J; Weisman, N; White, CM | 1 |
| Jones, G; Lipson, J; Wang, E | 1 |
| Kisely, S | 1 |
| Haridy, R | 1 |
| Nogrady, B | 1 |
| Bublitz, C; Langlitz, N; Repantis, D | 1 |
| Holstein, A; Klumpers, LE; Knowles, R; Mantuani, D; Tagen, M; van Heerden, L | 1 |
| Hoge, CW; Wolfgang, AS | 1 |
| Basbaum, A; Corder, G; Dworkin, RH; Edwards, RR; Eickhoff, CR; Eickhoff, SB; Larsen, B; Linguiti, S; McKinstry-Wu, A; Pines, A; Roalf, DR; Satterthwaite, TD; Scott, JC; Sharma, V; Strain, EC; Sydnor, VJ; Vogel, JW; Wellman, N | 1 |
| Reardon, S | 1 |
24 review(s) available for n-methyl-3,4-methylenedioxyamphetamine and psilocybin
| Article | Year |
|---|---|
Recreational drug misuse: issues for the cardiologist.
Topics: Adolescent; Adult; Amphetamines; Cannabis; Cardiovascular Diseases; Child; Cocaine; Drug Overdose; Female; Hallucinogens; Heroin; Humans; Lysergic Acid Diethylamide; Male; Morphine; N-Methyl-3,4-methylenedioxyamphetamine; Narcotics; Psilocybin; Substance-Related Disorders | 2000 |
Common drugs of abuse--Part II.
Topics: 4-Butyrolactone; Catha; Designer Drugs; Dibenzothiazepines; Diterpenes; Diterpenes, Clerodane; DOM 2,5-Dimethoxy-4-Methylamphetamine; Drug and Narcotic Control; Flunitrazepam; Hallucinogens; Humans; Illicit Drugs; Ketamine; Lysergic Acid Diethylamide; Methamphetamine; Motivation; N-Methyl-3,4-methylenedioxyamphetamine; Phencyclidine; Phenylpropanolamine; Piperazines; Psilocybin; Quetiapine Fumarate; Sodium Oxybate; Substance-Related Disorders; United States | 2004 |
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
Topics: Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology; Psychotropic Drugs; Randomized Controlled Trials as Topic | 2016 |
[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
Topics: Combined Modality Therapy; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy; Serotonin Agents; Treatment Outcome | 2017 |
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.
Topics: Animals; Data Collection; Emotions; Forecasting; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic | 2018 |
Psychedelic drugs-a new era in
psychiatry?
.
Topics: Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychiatry | 2019 |
Psychedelics and Psychedelic-Assisted Psychotherapy.
Topics: Evidence-Based Practice; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy | 2020 |
Compassionate use of psychedelics.
Topics: Chronic Disease; Compassionate Use Trials; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy; Terminal Care | 2020 |
The emerging role of psilocybin and MDMA in the treatment of mental illness.
Topics: Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2020 |
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
Topics: Animals; Brain; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; Mental Health; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Randomized Controlled Trials as Topic | 2021 |
Use and abuse of dissociative and psychedelic drugs in adolescence.
Topics: Adolescent; Adult; Age Factors; Animals; Dextromethorphan; Female; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Male; N-Methyl-3,4-methylenedioxyamphetamine; Phencyclidine; Psilocybin; Risk-Taking; Substance-Related Disorders | 2021 |
Therapeutic Potential of Psychedelics in the Treatment of Psychiatric Disorders, Part 1: Psychopharmacology and Neurobiological Effects.
Topics: Banisteriopsis; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology | 2021 |
Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2: Review of the Evidence.
Topics: Banisteriopsis; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2021 |
Psilocybin and MDMA for the treatment of trauma-related psychopathology.
Topics: Depressive Disorder, Major; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic; Treatment Outcome | 2021 |
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.
Topics: Adult; Drug Interactions; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy; Stress Disorders, Post-Traumatic | 2022 |
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.
Topics: Adult; Anxiety Disorders; Child; Cognitive Behavioral Therapy; Developmental Disabilities; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.
Topics: Cannabinoids; Fear; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic; United States | 2022 |
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.
Topics: Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Policy; Psilocybin; Substance Withdrawal Syndrome | 2022 |
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
Topics: Banisteriopsis; Hallucinogens; Headache; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2022 |
The Emerging Field of Psychedelic Psychotherapy.
Topics: Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy; Stress Disorders, Post-Traumatic | 2022 |
Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
Topics: Antidepressive Agents; Anxiety; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Neoplasms; Psilocybin; Randomized Controlled Trials as Topic | 2023 |
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
Topics: Hallucinogens; Heart Valve Diseases; Humans; Lysergic Acid Diethylamide; Mescaline; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Serotonin | 2023 |
Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.
Topics: Delivery of Health Care; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; United States; United States Department of Veterans Affairs; Veterans | 2023 |
Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.
Topics: Brain; Hallucinogens; Humans; Ketamine; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
4 trial(s) available for n-methyl-3,4-methylenedioxyamphetamine and psilocybin
| Article | Year |
|---|---|
Psychometric evaluation of the altered states of consciousness rating scale (OAV).
Topics: Adult; Cluster Analysis; Consciousness; Female; Humans; Ketamine; Male; Models, Theoretical; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychometrics; Reproducibility of Results; Surveys and Questionnaires | 2010 |
Psilocybin and MDMA reduce costly punishment in the Ultimatum Game.
Topics: Adult; Altruism; Community-Based Participatory Research; Decision Making; Emotions; Games, Experimental; Healthy Volunteers; Humans; Interpersonal Relations; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology; Punishment; Rejection, Psychology; Reward; Social Behavior; Socialization; Young Adult | 2018 |
Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.
Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy | 2021 |
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; National Institutes of Health (U.S.); Psilocybin; United States | 2022 |
23 other study(ies) available for n-methyl-3,4-methylenedioxyamphetamine and psilocybin
| Article | Year |
|---|---|
Psychedelic drugs: the ups and downs of ecstasy.
Topics: Agaricales; Animals; Anxiety; Brain; Cactaceae; Controlled Clinical Trials as Topic; Female; Hallucinogens; History, 20th Century; History, 21st Century; Humans; Lysergic Acid Diethylamide; Medicine, Traditional; Mescaline; N-Methyl-3,4-methylenedioxyamphetamine; Phytotherapy; Pilot Projects; Psilocybin; Psychotherapy; Stress Disorders, Post-Traumatic | 2004 |
Not imagining it. Research into hallucinogens cautiously resumes.
Topics: Controlled Clinical Trials as Topic; Double-Blind Method; Hallucinogens; Humans; Mysticism; N-Methyl-3,4-methylenedioxyamphetamine; N,N-Dimethyltryptamine; Psilocybin; Research; Spirituality | 2006 |
5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users.
Topics: Adult; Cross-Sectional Studies; Female; Hallucinogens; Humans; Incidence; Ketamine; Lysergic Acid Diethylamide; Male; N-Methyl-3,4-methylenedioxyamphetamine; Prevalence; Psilocybin; Substance-Related Disorders; United Kingdom | 2007 |
Psilocybin-induced stimulus control in the rat.
Topics: Animals; Conditioning, Operant; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Generalization, Stimulus; Hallucinogens; Lysergic Acid Diethylamide; Male; N-Methyl-3,4-methylenedioxyamphetamine; Phencyclidine; Psilocybin; Rats; Rats, Inbred F344; Reinforcement Schedule | 2007 |
Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.
Topics: Animals; Data Interpretation, Statistical; Discrimination Learning; Dose-Response Relationship, Drug; Fluorobenzenes; Hallucinogens; Lysergic Acid Diethylamide; Male; Mice; N-Methyl-3,4-methylenedioxyamphetamine; Piperazines; Piperidines; Psilocybin; Pyridines; Rats; Rats, Inbred F344; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Serotonin Antagonists; Tryptamines | 2008 |
Disruptive Psychopharmacology.
Topics: Consciousness; Humans; Ketamine; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychopharmacology; Psychotropic Drugs | 2019 |
Nothing Ventured, Nothing Gained: Regulations Cripple Potentially Life-Saving Research of Illicit Substances.
Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Substance-Related Disorders | 2020 |
How ecstasy and psilocybin are shaking up psychiatry.
Topics: Animals; Certification; Clinical Trials as Topic; Depression; Depressive Disorder, Treatment-Resistant; Drug Prescriptions; Efficiency; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; N,N-Dimethyltryptamine; Neuronal Plasticity; Niacin; Psilocybin; Psychiatry; Psychotherapy; Rumination, Cognitive; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic | 2021 |
Dosing Psychedelics and MDMA.
Topics: Hallucinogens; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; Pharmaceutical Preparations; Psilocybin | 2022 |
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.
Topics: Adolescent; Adult; Aged; Female; Hallucinogens; Health Surveys; Humans; Lysergic Acid Diethylamide; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress, Psychological; Substance-Related Disorders; Suicidal Ideation; United States; Young Adult | 2022 |
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Female; Hallucinogens; Health Surveys; Humans; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Patient Acuity; Psilocybin; Substance-Related Disorders; United States; Young Adult | 2022 |
Analysis of recreational psychedelic substance use experiences classified by substance.
Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Substance-Related Disorders | 2022 |
The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
Topics: Aged; Brain; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
Topics: Ethnicity; Hallucinogens; Humans; Minority Groups; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychological Distress; Suicide | 2022 |
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes.
Topics: Adult; Depressive Disorder, Major; Ethnicity; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
Psychedelic Drug Legislative Reform and Legalization in the US.
Topics: Adolescent; Aged; Educational Status; Female; Hallucinogens; Humans; Mescaline; N-Methyl-3,4-methylenedioxyamphetamine; Pregnancy; Psilocybin | 2023 |
Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents.
Topics: Adolescent; Child; Cross-Sectional Studies; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mescaline; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Suicidal Ideation | 2022 |
Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.
Topics: Adult; Hallucinogens; Humans; Mescaline; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Social Interaction; Substance Withdrawal Syndrome | 2023 |
The down-scheduling of MDMA and psilocybin(e): Too fast and too soon.
Topics: Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin | 2023 |
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
Topics: Australia; Depression; Drug Approval; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic; Time Factors | 2023 |
Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
Topics: Australia; Depression; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic | 2023 |
Control side effects of the psychedelic renaissance.
Topics: Drug Approval; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Prescription Drug Monitoring Programs; Psilocybin | 2023 |
Psychedelic treatments are speeding towards approval - but no one knows how they work.
Topics: Depression; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychological Trauma; Uncertainty | 2023 |